Celexa and Pathogen resistance - a phase IV clinical study of FDA data

Summary:

Pathogen resistance is reported as a side effect among people who take Celexa (citalopram hydrobromide), especially for people who are female, 40-49 old, also take Neurontin, and have Hepatitis c.

The phase IV clinical study analyzes which people have Pathogen resistance when taking Celexa. It is created by eHealthMe based on reports of 49,596 people who have side effects when taking Celexa from the FDA, and is updated regularly.

What is Celexa?

Celexa has active ingredients of citalopram hydrobromide. It is often used in depression. eHealthMe is studying from 56,390 Celexa users. Check the latest studies of Celexa.

What is Pathogen resistance?

Pathogen resistance is found to be associated with 445 drugs and 596 conditions by eHealthMe. Check the latest studies of Pathogen resistance.

On Jul, 09, 2026

49,596 people reported to have side effects when taking Celexa.
Among them, 11 people (0.02%) have Pathogen resistance.

Among these 11 people:

What is the gender of people who have Pathogen resistance when taking Celexa? *

female: 81.82 %
male: 18.18 %

What is the age of people who have Pathogen resistance when taking Celexa? *

What are other drugs people take besides Celexa? *

What are other side effects people have besides Pathogen resistance? *

Staphylococcal Infection (an infection with staphylococcus bacteria): 6 people, 54.55%
Fever: 5 people, 45.45%
Enterococcal Infection: 4 people, 36.36%
Fatigue (feeling of tiredness): 4 people, 36.36%
Urinary Tract Infection: 4 people, 36.36%
Pain: 4 people, 36.36%
Headache (pain in head): 3 people, 27.27%
Dehydration (dryness resulting from the removal of water): 3 people, 27.27%
Sinus Disorder (disease of sinus): 3 people, 27.27%
Sinusitis (inflammation of sinus): 3 people, 27.27%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 18.18%
Hepatitis C: 2 people, 18.18%
Multiple Myeloma (cancer of the plasma cells): 1 person, 9.09%
Irritable Bowel Syndrome: 1 person, 9.09%
High Blood Pressure: 1 person, 9.09%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%
Fungaemia (fungi circulate in the blood): 1 person, 9.09%
Back Pain: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Celexa and have Pathogen resistance?

- Check whether Pathogen resistance is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Celexa:

Celexa (56,390 reports)

Browse all side effects of Celexa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pathogen resistance:

Pathogen resistance (445 drugs)

Browse all the conditions that are associated with Pathogen resistance:

Pathogen resistance (596 conditions)

Related publications that referenced our studies

Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .
Hosseini, S. H., & Ahmadi, A., "Peripheral edema occurring during treatment with risperidone combined with citalopram", Case reports in medicine, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on citalopram hydrobromide (the active ingredients of Celexa) and Celexa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.